# Study on the Efficacy and Safety of QLM1016 in Schizophrenia

> **NCT06799559** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 402 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** 3-6mg QLM1016
- **DRUG:** 10-20 mg Aripiprazole oral solution film

## Key facts

- **NCT ID:** NCT06799559
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799559, "Study on the Efficacy and Safety of QLM1016 in Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06799559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*